Literature DB >> 18784071

Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis.

Uttamkumar Samanta1, Brian J Bahnson.   

Abstract

Human plasma platelet-activating factor (PAF) acetylhydrolase functions by reducing PAF levels as a general anti-inflammatory scavenger and is linked to anaphylactic shock, asthma, and allergic reactions. The enzyme has also been implicated in hydrolytic activities of other pro-inflammatory agents, such as sn-2 oxidatively fragmented phospholipids. This plasma enzyme is tightly bound to low and high density lipoprotein particles and is also referred to as lipoprotein-associated phospholipase A2. The crystal structure of this enzyme has been solved from x-ray diffraction data collected to a resolution of 1.5 angstroms. It has a classic lipase alpha/beta-hydrolase fold, and it contains a catalytic triad of Ser273, His351, and Asp296. Two clusters of hydrophobic residues define the probable interface-binding region, and a prediction is given of how the enzyme is bound to lipoproteins. Additionally, an acidic patch of 10 carboxylate residues and a neighboring basic patch of three residues are suggested to play a role in high density lipoprotein/low density lipoprotein partitioning. A crystal structure is also presented of PAF acetylhydrolase reacted with the organophosphate compound paraoxon via its active site Ser273. The resulting diethyl phosphoryl complex was used to model the tetrahedral intermediate of the substrate PAF to the active site. The model of interface binding begins to explain the known specificity of lipoprotein-bound substrates and how the active site can be both close to the hydrophobic-hydrophilic interface and at the same time be accessible to the aqueous phase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784071      PMCID: PMC2581546          DOI: 10.1074/jbc.M804750200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Do membrane-bound enzymes access their substrates from the membrane or aqueous phase: interfacial versus non-interfacial enzymes.

Authors:  M H Gelb; J H Min; M K Jain
Journal:  Biochim Biophys Acta       Date:  2000-10-31

2.  Automated protein model building combined with iterative structure refinement.

Authors:  A Perrakis; R Morris; V S Lamzin
Journal:  Nat Struct Biol       Date:  1999-05

3.  Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase.

Authors:  J H Min; M K Jain; C Wilder; L Paul; R Apitz-Castro; D C Aspleaf; M H Gelb
Journal:  Biochemistry       Date:  1999-09-28       Impact factor: 3.162

4.  The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.

Authors:  S Kruse; X Q Mao; A Heinzmann; S Blattmann; M H Roberts; S Braun; P S Gao; J Forster; J Kuehr; J M Hopkin; T Shirakawa; K A Deichmann
Journal:  Am J Hum Genet       Date:  2000-03-24       Impact factor: 11.025

5.  Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme.

Authors:  J H Min; C Wilder; J Aoki; H Arai; K Inoue; L Paul; M H Gelb
Journal:  Biochemistry       Date:  2001-04-17       Impact factor: 3.162

6.  Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.

Authors:  D M Stafforini; T Numao; A Tsodikov; D Vaitkus; T Fukuda; N Watanabe; N Fueki; T M McIntyre; G A Zimmerman; S Makino; S M Prescott
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 7.  Platelet-activating factor and related lipid mediators.

Authors:  S M Prescott; G A Zimmerman; D M Stafforini; T M McIntyre
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 8.  Platelet-activating factor acetylhydrolases in health and disease.

Authors:  L W Tjoelker; D M Stafforini
Journal:  Biochim Biophys Acta       Date:  2000-10-31

9.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

10.  Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein.

Authors:  D M Stafforini; L W Tjoelker; S P McCormick; D Vaitkus; T M McIntyre; P W Gray; S G Young; S M Prescott
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

View more
  24 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Trafficking of platelet-activating factor acetylhydrolase type II in response to oxidative stress.

Authors:  Anastasia F Thévenin; Elizabeth S Monillas; Jason M Winget; Kirk Czymmek; Brian J Bahnson
Journal:  Biochemistry       Date:  2011-09-12       Impact factor: 3.162

Review 3.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

4.  A robust all-atom model for LCAT generated by homology modeling.

Authors:  Jere P Segrest; Martin K Jones; Andrea Catte; Saravana P Thirumuruganandham
Journal:  J Lipid Res       Date:  2015-01-14       Impact factor: 5.922

Review 5.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

6.  Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA2 Inhibitor.

Authors:  Nicholas D Measom; Kenneth D Down; David J Hirst; Craig Jamieson; Eric S Manas; Vipulkumar K Patel; Don O Somers
Journal:  ACS Med Chem Lett       Date:  2016-11-15       Impact factor: 4.345

7.  Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.

Authors:  Kasey C Vickers; Colin T Maguire; Robert Wolfert; Alan R Burns; Michael Reardon; Richard Geis; Paul Holvoet; Joel D Morrisett
Journal:  J Lipid Res       Date:  2009-04-09       Impact factor: 5.922

8.  Crystal structures of brain group-VIII phospholipase A2 in nonaged complexes with the organophosphorus nerve agents soman and sarin.

Authors:  Todd M Epstein; Uttamkumar Samanta; Stephen D Kirby; Douglas M Cerasoli; Brian J Bahnson
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

Review 9.  Using hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase A2 superfamily with lipid substrates, inhibitors, and membranes.

Authors:  Jian Cao; John E Burke; Edward A Dennis
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

10.  Crystal structures of human group-VIIA phospholipase A2 inhibited by organophosphorus nerve agents exhibit non-aged complexes.

Authors:  Uttamkumar Samanta; Stephen D Kirby; Prabhavathi Srinivasan; Douglas M Cerasoli; Brian J Bahnson
Journal:  Biochem Pharmacol       Date:  2009-04-24       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.